Stock AnalizBecton Dickinson & Co. BDX
Medical/Dental Instruments · data as of November 13, 2026
Becton Dickinson & Co. (BDX) is a healthcare company listed in the US with a market value of about $59.4B. In the twelve months to September 30, 2026 it had revenue of $19.5B and net income of $1.1B, a net margin of 5.9%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is value (0/5).
Key numbers: a P/E of 43.1, a price to free cash flow of 22.0, 5-year revenue growth of 6% a year, a 5-year average ROIC of 5%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 41% below the current price.
Score: 2.0 / 5
Checks passed
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- Profitable 5 years in a row
- Positive free cash flow
- Liabilities below 60% of assets
- Pays a dividend
- 20% to 100% of free cash flow returned to shareholders
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5B | $21.8B | $20.2B | $19.4B | $18.9B | $19.1B | $16.1B | $17.3B | $16.0B | $12.1B | $12.5B |
| Net income | $1.1B | $1.7B | $1.7B | $1.5B | $1.8B | $2.1B | $874M | $1.2B | $311M | $1.1B | $976M |
| Free cash flow | $2.7B | $2.7B | $3.1B | $2.1B | $1.5B | $3.5B | $2.8B | $2.4B | $2.0B | $1.8B | $1.9B |
| EPS (diluted) | $4.09 | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 | $2.71 | $3.94 | $0.60 | $4.60 | $4.49 |
| Net margin | 5.9% | 7.7% | 8.5% | 7.7% | 9.4% | 10.9% | 5.4% | 7.1% | 1.9% | 9.1% | 7.8% |
| ROIC | — | 5.1% | 4.3% | 4.6% | 5.0% | 5.1% | 1.8% | 3.4% | 2.8% | 3.8% | 6.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $226.14, 4% above the current price; targets range from $195.00 to $242.00; the consensus rating is “Buy”; expected EPS is $13.22 for the fiscal year ending September 30, 2027.
Frequently asked questions
What is Becton Dickinson &’s P/E ratio?
About 43.1, based on the last twelve months of diluted earnings per share (forward P/E about 17.5).
Is Becton Dickinson & stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 41% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Becton Dickinson & pay a dividend?
Yes. The dividend yield is about 1.98%, and it has paid dividends for 10 years in our data.
Is Becton Dickinson & a good stock to buy?
We do not give buy or sell advice. Becton Dickinson & scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.